Physician profile
Brook A Saunders
NPI 1851475602
$892.19
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $123 · 2021: $20.36 · 2022: $134 · 2023: $364 · 2024: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $298.66 | 2020-2024 | Zejula, Jemperli |
| Intuitive Surgical, INC. | $170.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $76.91 | 2022-2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $55.03 | 2023-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $42.29 | 2022-2023 | Ninlaro |
| Genentech USA, INC. | $39.74 | 2023-2024 | Polivy, Lunsumio, Phesgo |
| Morphosys, US INC. | $35.73 | 2022-2023 | Monjuvi |
| Amgen INC. | $33.60 | 2023 | Lumakras, Xgeva, Vectibix |
| Seagen INC. | $23.25 | 2023 | Adcetris |
| Puma Biotechnology, INC. | $23.10 | 2023 | |
| Janssen Biotech, INC. | $22.17 | 2022 | |
| Clovis Oncology, INC. | $20.36 | 2021 | |
| Daiichi Sankyo INC. | $19.38 | 2024 | Injectafer |
| Myriad Genetic Laboratories, INC. | $15.77 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brook Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.